ABIO to break $1.00 today and DARA is in some big pharma's cross hairs for sure...Hot Off the Presses - NEW YORK, NY -- (Marketwire) -- 02/01/13 -- Lost revenues from expiring patents has played a major part in the Biotech Industry's success in recent years. A total of 676 takeovers of biotechnology and pharmaceutical companies have occurred in the past three years, with an average premium of 38 percent, according to data collected by Bloomberg. Five Star Equities examines the outlook for companies in the Biotech Industry
Please stop with ABIO. It will come crashing back to earth-- its catalysts stink, who is buying this? DARA on the other hand-- it about as good as it gets. Value of its radiation meds worth more then current market cap, I don't see any down side risk. Financing in place to 2015 with DARA-- again no down side risk due to dilution. Also-- the catalysts for DARA are potential blockbusters-- being fasttracked due to demand-- and its neuropathy drug, which already had a positive 2a trial-- could make this a 500 million dollar company-- no pumping here. It something nearly all cancer patients receiving chemotherapy could benefit from. The bottom line, low risk, huge reward in DARA-- that is the kind of company I like to invest in.